Alivus Life Sciences Limited

rs,

vember 17, 2022 To, Dy. General Manager Department of Corporate Services, BSE Ltd., P. J. Towers, Dalal Street, Fort, Mumbai – 400 001 To, The Manager - Listing, National Stock Exchange of Indi

15%

0+ 10+ 17 10+ 16 Strategic Market Expansion Revenue Break-up Revenue Break-up North America 15% Emerging Markets 19% Other markets Geographic Growth from 2019 to 2022 (3 year CAGR)* Latam

19%

trategic Market Expansion Revenue Break-up Revenue Break-up North America 15% Emerging Markets 19% Other markets Geographic Growth from 2019 to 2022 (3 year CAGR)* Latam 19% Revenue Break-up R

11%

h from 2019 to 2022 (3 year CAGR)* Latam 19% Revenue Break-up Revenue Break-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022

13%

9 to 2022 (3 year CAGR)* Latam 19% Revenue Break-up Revenue Break-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7%

3%

(3 year CAGR)* Latam 19% Revenue Break-up Revenue Break-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20%

31%

Break-up Revenue Break-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (

10%

venue Break-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (Note: India

14%

ak-up North America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (Note: India growth –

16%

h America 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (Note: India growth – ex GPL numb

55%

erica 11% Latam 13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (Note: India growth – ex GPL numbers)

7%

13% Japan 3% 2019 Japan India 19% Europe 31% India 10% EM 14% Latam 16% 55% 2022 Japan 7% India 20% (Note: Excluding sales to GPL) (Note: India growth – ex GPL numbers) (Note: Excludin

Note

1

Note

▪ ▪ FY20 – 3 products extended to multiple markets FY21 and FY22 – 1 product extended to multiple markets FY19 H1FY23 8 9 8 23 80+ > 30% 20 - 30% 10 - 20% < 10% 222724431222432222FY20FY21FY22Existing APIs extended to new marketsEMEuropeIndiaJapanLatamNorth America Broader Portfolio reduces dependence on Top APIs Top 5 Top 15 Chronic Vs Acute Key Therapeutic areas Revenue contribution by APIs 27.8% 57.5% No. of Customers 55 219 36.1% 61.0% 57.5% 27.8% Evolution of Top APIs (% of Revenue) FY19 FY22 FY19 FY22 9 Diabetes CVS Others CNS Pain Management 39% 32% 36% 37% 5% 5% 4% 4% 40% 45% 42% 38% 28% 7% 43% 9% 7% 9% 10% 9% 8% 14% 7% 14% 7% FY19 FY20 FY21 FY22 H1FY23 Key Drivers for Sustainable Operations cGMP Compliant Manufacturing • • • 3 US-FDA Inspected plants Excellent track record with regulatory inspections 38 Regulatory inspections since 2015 Safety Environment Management People Operational Efficiency • • • Process Safety Engineering Controls Personal protective equipment • Control o